Leukemias, lymphomas, and other hematologic cancers:

Indications for: TARGRETIN GEL

Cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.

Adult Dosage:

Apply once every other day for the 1st week; then increase frequency at weekly intervals to once daily, then twice daily, then 3 times daily, then 4 times daily based on lesion tolerance. Usual dosing frequency: 2–4 times daily; may reduce if application site toxicity occurs. Allow gel to dry. Do not occlude.

Children Dosage:

Not established.

TARGRETIN GEL Contraindications:

Pregnancy.

TARGRETIN GEL Warnings/Precautions:

Be fully familiar with this drug's toxicity before use. Counsel patients monthly about need for contraception. Females of reproductive potential: obtain reliable negative pregnancy test within 1 week of start; repeat monthly. Start therapy on 2nd or 3rd day of normal menstrual period. Use two effective forms of contraception 1 month prior to, during, and for 1 month after therapy. Max 1 month/℞. Males with partners who are or may become pregnant: use condoms during and for at least 1 month after therapy. Hepatic or renal impairment. Discontinue temporarily if severe irritation occurs. Avoid sun, UV light, and mucosal membranes. Nursing mothers: not recommended.

TARGRETIN GEL Classification:

Retinoid.

TARGRETIN GEL Interactions:

Avoid concomitant products that contain DEET. May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice). Caution with gemfibrozil. Limit Vit. A supplements to avoid toxicity.

Adverse Reactions:

Application site reactions (eg, rash, pruritus, skin disorders, pain, contact dermatitis).

How Supplied:

Gel—60g